Association between the 21-gene recurrence score assay (RS) and risk of locoregional failure in node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.

被引：0
|
作者：
Mamounas, E
Tang, G
Bryant, J
Paik, S
Shak, S
Costantino, J
Watson, D
Wickerham, DL
Wolmark, N
机构：
[1] NSABP, Pittsburgh, PA USA
[2] Aultman Hlth Fdn, Canton, OH USA
[3] Genom Hlth Inc, Redwood City, CA USA
[4] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S16 / S16
页数：1
相关论文
共 50 条
  • [21] A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores
    Takeo Fujii
    Hiroko Masuda
    Yee Chung Cheng
    Fei Yang
    Aysegul A. Sahin
    Yasuto Naoi
    Yuki Matsunaga
    Akshara Raghavendra
    Arup Kumar Sinha
    Jose Rodrigo Espinosa Fernandez
    Anjali James
    Keisuke Yamagishi
    Tomoko Matsushima
    Robert Schuetz
    Debu Tripathy
    Sachiyo Tada
    Rubie S. Jackson
    Shinzaburo Noguchi
    Seigo Nakamura
    Jared D. Acoba
    Naoto T. Ueno
    Breast Cancer Research and Treatment, 2021, 189 : 455 - 461
  • [22] A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores
    Fujii, Takeo
    Masuda, Hiroko
    Cheng, Yee Chung
    Yang, Fei
    Sahin, Aysegul A.
    Naoi, Yasuto
    Matsunaga, Yuki
    Raghavendra, Akshara
    Sinha, Arup Kumar
    Fernandez, Jose Rodrigo Espinosa
    James, Anjali
    Yamagishi, Keisuke
    Matsushima, Tomoko
    Schuetz, Robert
    Tripathy, Debu
    Tada, Sachiyo
    Jackson, Rubie S.
    Noguchi, Shinzaburo
    Nakamura, Seigo
    Acoba, Jared D.
    Ueno, Naoto T.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (02) : 455 - 461
  • [23] Clinical significance of 21-gene recurrence score assay for hormone receptor-positive, lymph node-negative breast cancer in early stage
    Yang Yu-qing
    Wang Lei
    Huang Mei-ling
    Xiao Jing-jing
    Wei Mei-chen
    Wu Jiang
    Hao Jun-sheng
    Ling Rui
    Li Nan-lin
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2019, 108 : 150 - 155
  • [24] Predictive value of 21-gene recurrence score assay in non-estrogen receptor-positive and lymph node-negative breast cancer
    Lu, Kai
    Li, Hui
    Wu, Zhaoshu
    Liu, Dong
    Ye, Hongling
    Xu, Liang
    Liu, Yanwen
    JOURNAL OF BUON, 2018, 23 (05): : 1297 - 1301
  • [25] Prognostic value of the 21-gene recurrence score in ER-positive,HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients
    Jiayi Wu
    Weiqi Gao
    Xiaosong Chen
    Chunxiao Fei
    Lin Lin
    Weiguo Chen
    Ou Huang
    Siji Zhu
    Jianrong He
    Yafen Li
    Li Zhu
    Kunwei Shen
    Frontiers of Medicine, 2021, 15 (04) : 621 - 628
  • [26] Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients
    Jiayi Wu
    Weiqi Gao
    Xiaosong Chen
    Chunxiao Fei
    Lin Lin
    Weiguo Chen
    Ou Huang
    Siji Zhu
    Jianrong He
    Yafen Li
    Li Zhu
    Kunwei Shen
    Frontiers of Medicine, 2021, 15 : 621 - 628
  • [27] Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients
    Wu, Jiayi
    Gao, Weiqi
    Chen, Xiaosong
    Fei, Chunxiao
    Lin, Lin
    Chen, Weiguo
    Huang, Ou
    Zhu, Siji
    He, Jianrong
    Li, Yafen
    Zhu, Li
    Shen, Kunwei
    FRONTIERS OF MEDICINE, 2021, 15 (04) : 621 - 628
  • [28] Impact of the 21-gene recurrence score assay in adjuvant chemotherapy selection for node-negative, hormone receptor-positive breast cancer in the Chinese population
    Zhang, Y. N.
    Zhou, Y. D.
    Mao, F.
    Sun, Q.
    NEOPLASMA, 2015, 62 (04) : 658 - 665
  • [29] Using the 21-gene recurrence score and the recently developed Recurrence Score-Clinical-Pathologic to assess recurrence risk in patients with node-negative, ER-positive early-stage breast cancer receiving aromatase inhibitor treatment alone.
    Crager, M.
    Tang, G.
    Shak, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100)
    Albain, K.
    Barlow, W.
    Shak, S.
    Hortobagyi, G.
    Livingston, R.
    Yeh, I.
    Ravdin, P.
    Yoshizawa, C.
    Baehner, F.
    Davidson, N.
    Sledge, G.
    Winer, E.
    Hudis, C.
    Ingle, J.
    Perez, E.
    Pritchard, K.
    Shepherd, L.
    Allred, C.
    Osborne, K.
    Hayes, D.
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (03) : 585 - 585
12345